Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Atripla | Efavirenz, emtricitabine, tenofovir disoproxil fumarate | HIV | List with clinical criteria and/or conditions | Complete | ||
| Invega | Paliperidone | Schizophrenia | Do not list | Complete | ||
| Celsentri | Maraviroc | HIV | Withdrawn | |||
| Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder, Adult | Do not list | Complete | ||
| Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | ||
| Isentress | Raltegravir | HIV | List with clinical criteria and/or conditions | Complete | ||
| Rasilez | Aliskiren | Hypertension | Do not list | Complete | ||
| Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | Do not list | Complete | ||
| Exelon Patch | Rivastigmine | Dementia (Alzheimer's type) | Do not list | Complete |
Last Updated : May 20, 2024